Bringing Immuno-Oncology Into Focus
Advanta IO Gene Expression Assay and Workflow
Tumor gene expression has proven to be an effective measure of immune response in cancer progression and therapeutic response research. As emerging therapies reveal new biomarkers and expand the need for samples, the costs and labor required to complete this important work increase. The Advanta™ IO Gene Expression Assay, used with the Biomark™ HD system, provides a sensitive and cost-effective toolset for identifying gene expression signatures from immune and cancer cells.
A powerful immuno-oncology focused assay
The Advanta IO Gene Expression Assay was developed in collaboration with leading researchers in the biopharmaceutical industry to provide the optimal balance of biomarker breadth, assay flexibility and workflow efficiency.
The panel consists of 170 genes, including 91 reported in Nature, where Roy Herbst et al. defined a gene set representing tumor and immune response. The panel includes markers for:
- Immune cell identification
- Immune and cancer cell function
- Immune regulation and cell fate
- Checkpoint therapy response
Optimized for formalin-fixed, paraffin-embedded and fresh frozen tumor samples, the Advanta IO Gene Expression Assay uses TaqMan® chemistry to sensitively measure gene expression, with five reference genes serving as analysis controls. Combined with Standard BioTools™ microfluidics technology, the assay offers significant workflow efficiencies over traditional gene expression profiling methods. Each reaction is miniaturized to nanoliter volume and controlled using precise automation to facilitate qPCR analysis across a large dynamic range. With assay introduction into the integrated fluidic circuit (IFC) under user control, researchers have the flexibility to add up to 17 new assays or exchange gene assays within the panel to achieve experimental goals without compromise.
Download the flyer to learn more about the Advanta IO Gene Expression Assay workflow using the Biomark HD system, and to see the list of gene expression targets covered in the assay.
Sample case study
In a 2016 paper published by The Lancet for the POPLAR study, “Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer,” Louis Fehrenbacher et al. used immunohistochemistry, and also ran a gene expression panel of 91 genes featured in the Herbst paper. These genes are included in the Advanta IO Gene Expression Assay.
The team subsequently used these research results to develop a gene signature based on a subset of the panel, that provided data that could potentially be used for developing future diagnostics tests.
Learn more about how our customers are leveraging Standard BioTools technology